| Literature DB >> 35001897 |
Iris van der Lijn1,2, Gera A de Haan1,2, Famke Huizinga1,3, Fleur E van der Feen1,2, A Wijnand F Rutgers4, Catherina Stellingwerf2, Teus van Laar5, Joost Heutink1,2.
Abstract
BACKGROUND: Scientific research increasingly focuses on visual symptoms of people with Parkinson's disease (PD). However, this mostly involves functional measures, whereas self-reported data are equally important for guiding clinical care.Entities:
Keywords: Activities of daily living; Parkinson’s disease; quality of life; self report; systematic review; vision disorders
Mesh:
Year: 2022 PMID: 35001897 PMCID: PMC9108577 DOI: 10.3233/JPD-202324
Source DB: PubMed Journal: J Parkinsons Dis ISSN: 1877-7171 Impact factor: 5.520
Search terms for literature search
| Search 1 | Terms used in all databases | MeSH and thesaurus terms used in PubMed or PsycInfo |
| First criterion | parkinson*a | |
| Second criterion | “self report”, complaint*, “subjective assessment*”, “subjective measure*”, “subjective problem*”, “subjective dysfunction*”, “subjective deficit*”, “subjective impairment*”, “subjective symptom*”, “report a problem”, “report problem*”, “report a dysfunction”, “report dysfunction*”, “report a deficit”, “report deficit*”, “report an impairment”, “report impairment*”, “report a symptom”, “report symptom*”, “reports a problem”, “reports problem*”, “reports a dysfunction”, “reports dysfunction*”, “reports a deficit”, “reports deficit*”, “reports an impairment”, “reports impairment*”, “reports a symptom”, “reports symptom*”, “reported a problem”, “reported problem*”, “reported a dysfunction”, “reported dysfunction*”, “reported a deficit”, “reported deficit*”, “reported an impairment”, “reported impairment*”, “reported a symptom”, “reported symptom*”, “perceive a problem”, “perceive problem*”, “perceive a dysfunction”, “perceive dysfunction*”, “perceive a deficit”, “perceive deficit*”, “perceive an impairment”, “perceive impairment*”, “perceive a symptom”, “perceive symptom*”, “perceives a problem”, “perceives problem*”, “perceives a dysfunction”, “perceives dysfunction*”, “perceives a deficit”, “perceives deficit*”, “perceives an impairment”, “perceives impairment*”, “perceives a symptom”, “perceives symptom*”, “perceived a problem”, “perceived problem*”, “perceived a dysfunction”, “perceived dysfunction*”, “perceived a deficit”, “perceived deficit*”, “perceived an impairment”, “perceived impairment*”, “perceived a symptom”, “perceived symptom*”, “experience a problem”, “experience problem*”, “experience a dysfunction”, “experience dysfunction*”, “experience a deficit”, “experience deficit*”, “experience an impairment”, “experience impairment*”, “experience a symptom”, “experience symptom*”, “experiences a problem”, “experiences problem*”, “experiences a dysfunction”, “experiences dysfunction*”, “experiences a deficit”, “experiences deficit*”, “experiences an impairment”, “experiences impairment*”, “experiences a symptom”, “experiences symptom*”, “experienced a problem”, “experienced problem*”, “experienced a dysfunction”, “experienced dysfunction*”, “experienced a deficit”, “experienced deficit*”, “experienced an impairment”, “experienced impairment*”, “experienced a symptom”, “experienced symptom*”b | |
| Search 2 | Terms used in all databases | MeSH and thesaurus terms used in PubMed or PsycInfo |
| First criterion | parkinson*a | |
| Second criterion | questionnaire*, scale*, survey*, inventor*, interview*b | |
| Third criterion | seeing OR eyesight OR sight OR ophthalmologic* OR “visual perception” OR “visual acuity” OR “visual field*” OR diplopia OR “double vision” OR “depth perception” OR “color vision” OR “colour vision” OR “color perception” OR “colour perception” OR “contrast sensitivity” OR “visual contrast” OR “brightness perception” OR “light sensitivity” OR “sensitive to light” OR “sensitivity to light” OR “oversensitive to light” OR “oversensitivity to light” OR photophobia OR photosensitivity OR glare OR “dark adaptation” OR “visual overload” OR “problems reading” OR “reading problem*” OR “difficulty reading” OR “reading difficult*” OR “painful eyes” OR “dry eyes” OR “eyelid opening” OR blink* OR “facial recognition” OR “face recognition” OR “face perception” OR “object recognition” OR “object perception” OR “figure perception” OR “form perception” OR “shape perception” OR “motion perception” OR “space perception” OR “spatial perception” OR “spatial orientation” OR “spatial disorientation” OR afterimage* OR “visual discrimination” OR “figure ground discrimination” OR “nonmotor symptom*” OR “non-motor symptom*” OR “autonomic dysfunction*” OR “autonomic symptom*” OR “autonomous dysfunction” OR “autonomous symptom*”b |
aTerm should be present in title or abstract, bOne of the terms should be present in the content of the paper.
Fig. 1PRISMA flow diagram of systematic literature search [14].
Overview of the prevalence of visual complaints in people with PD and the comparison to healthy controls
| Items covering complaint | Criterion presence complaint | Studies | PD patients | Prevalence PD patients (%) | Controls | Prevalence controls (%) | Studies PD > Controlsa
| Studies PD = Controls or PD < Controlsa
| |
|
| |||||||||
| Visual complaints in general | 17 | 2337 | 26.8 – 98 | 29344 | 16.1 – 31.6 | 6 | 0 | ||
| CIRS-G | 1 | ≥1 on a 0 (‘no problem’) – 4 (‘extremely severe’) scale | 1 [ | 76 | 98 | N/A | N/A | N/A | N/A |
| VFQ-25 | 25 | At least one complaint | 3 [ | 145 | 83.1 [ | 466 | 31.6 [ | 3 | 0 |
| Direct asking of the patient according to ICF checklist | 2 | ≥1 (‘mild difficulty’) on a 0 – 4 scale | 1 [ | 96 | 75.5b | N/A | N/A | N/A | N/A |
| Interview on autonomic dysfunction | 4 | N/A | 1 [ | 26 | 67 | 27 | 22 | 1 | 0 |
| Questionnaire on visual complaints (20-item) | N/A | N/A | 1 [ | 30 | 63.3 | 31 | 29.0 | 1 | 0 |
| PRO-PD | 1 | ≥5 on a 0 (‘lack of symptom’) – 100 (‘maximum severity’) scale | 1 [ | 1031 | 58.0 | N/A | N/A | N/A | N/A |
| Self-report questionnaire (31-item) | N/A | At least one complaint | 1 [ | 81 | 78c | N/A | N/A | N/A | N/A |
| Survey of Health, Ageing, and Retirement in Europe | 1 | ≥4 on a 1 (‘excellent’) – 5 (‘poor’) scale | 1 [ | 191 | 46.1 | 28820 | 16.1 | 1 | 0 |
| Interview using a questionnaire on non-motor symptoms [ | 1 | ‘yes’ | 2 [ | 76 | 46.1 | N/A | N/A | N/A | N/A |
| Symptom questionnaire | 1 | ‘yes’ | 1 [ | 39 | 43.6 | N/A | N/A | N/A | N/A |
| Question: are you bothered due to vision-related problems? | 1 | N/A | 1 [ | 295 | 41 | N/A | N/A | N/A | N/A |
| Structured interview | N/A | N/A | 1 [ | 108 | 40.7 | N/A | N/A | N/A | N/A |
| Symptom index (20-item) | 1 | ‘yes’ | 1 [ | 61 | 36.1 | N/A | N/A | N/A | N/A |
| Questions on visual complaints | N/A | N/A | 1 [ | 82 | 26.8 | N/A | N/A | N/A | N/A |
| Double vision | 96 | 20994 | 7.7 – 53.1 | 1556 | 2.4 – 19.0 | 15 | 3 | ||
| Questionnaire on changes in vision | 1 | ‘sometimes’ or ‘often’ | 2 [ | 237 | 53.1 | 100 | 19.0 | 2 | 0 |
| Self-report questionnaire (31-item) | 1 | ‘sometimes’ or ‘often’ | 1 [ | 81 | 38.0 | N/A | N/A | N/A | N/A |
| VIPD-Q | 1 | ≥2 (‘weekly’) on a 0 (‘never’) – 3 (‘daily’) scale | 1 [ | 848 | 22 | 250 | 3 | 1 | 0 |
| Questionnaire derived from VFQ-25 | N/A | N/A | 2 [ | 178 | 19.8 | 122 | 2.4 | 2 | 0 |
| Non-motor fluctuations questionnaire | 1 | N/A | 1 [ | 11 | 18.2 | N/A | N/A | N/A | N/A |
| NMSQ | 1 | ≥1 (‘yes’) | 61 [ | 11511 | 13.9d | 690 | 3.5 [ | 6 [47, 48, 56, 57, 59, 91] | 2 [ |
| NMSS | 1 | ≥1 (‘mild’) on a 0 (‘none’) – 3 (‘severe’) scale | 24 [ | 7545 | 14.2 [9, 41, 94, 96– 107, 109– 115] | 363 | 2.4 94, 96] | 3 [ | 1 [ |
| Online symptom survey | 1 | ‘yes’ | 1 [ | 432 | 12.7 | N/A | N/A | N/A | N/A |
| Questionnaire on visual complaints (20-item) | N/A | N/A | 1 [ | 30 | 10.0 | 31 | 3.2 | 1 | 0 |
| Questions on visual complaints | N/A | N/A | 1 [ | 82 | 9.8 | N/A | N/A | N/A | N/A |
| Questions on asthenopia | N/A | N/A | 1 [ | 39 | 7.7 | N/A | N/A | N/A | N/A |
| Increased sensitivity to light | 27 | 6318 | 15.0 – 48 | 1480 | 0 – 28.3 | 13 | 2 | ||
| Interview on autonomic dysfunction | 1 | N/A | 1 [ | 26 | 48 | N/A | N/A | N/A | N/A |
| VIPD-Q | 1 | ≥2 (‘weekly’) on a 0 (‘never’) – 3 (‘daily’) scale | 1 [ | 848 | 43 | 250 | 23 | 1 | 0 |
| ADS (autonomic dysfunction score) | 1 | N/A | 1 [ | 21 | 38.1 | 27 | 0 | 1 | 0 |
| SCOPA-AUT | 1 | ≥1 (‘sometimes’) on a 0 (‘never’) – 3 (‘often’) scale | 19 [ | 5195 | 31.8 [ | 1044 | 28.3 [120, 128– 130, 132, 138] | 8 [120, 121, 123, 128– 130, 132, 138] | 1 [ |
| COMPASS-31 | 5 | N/A | 1 [ | 47 | 27.7 | N/A | N/A | N/A | N/A |
| Questionnaire derived from VFQ-25 | N/A | N/A | 1 [ | 88 | 23.9 | 90 | 11.8 | 1 | 0 |
| Questionnaire on changes in vision | 1 | ‘sometimes’ or ‘often’ | 1 [ | 53 | 15 | 31 | 3 | 1 | 0 |
| VAQ | 3 | N/A | 1 [ | 25 | N/A | 23 | N/A | 0 | 1 |
| COMPASS | 7 | N/A | 1 [ | 15 | N/A | 15 | N/A | 1 | 0 |
| Altered color vision | 9 | 1394 | 4.1 – 12.7 | 894 | 3 – 10 | 4 | 4 | ||
| Questionnaire on changes in vision | 1 | ‘sometimes’ or ‘often’ | 2 [ | 237 | 12.7 | 100 | 4.4 | 1 [ | 1 [ |
| VIPD-Q | 1 | ≥2 (‘weekly’) on a 0 (‘never’) – 3 (‘daily’) scale | 1 [ | 848 | 11 | 250 | 3 | 1 | 0 |
| Questions on visual complaints | N/A | N/A | 1 [ | 82 | 6.1 | N/A | N/A | N/A | N/A |
| Interview on prodromal symptoms | 1 | ‘yes’ | 2 [ | 145 | 4.1 | 145 | 10 | 0 | 2 |
| VFQ-25 | 1 | N/A | 2 [ | 57 | N/A | 376 | N/A | 2 | 0 |
| VAQ | 3 | N/A | 1 [ | 25 | N/A | 23 | N/A | 0 | 1 |
| Painful/dry eyes | 9 | 1706 | 6.1 – 87.5 | 850 | 8 – 22.4 | 5 | 1 | ||
| Dry eye symptom assessment | ‘various’ | ≥2-3 times a week (‘occasionally’) | 1 [ | 56 | 87.5 | 34 | 20.6 | 1 | 0 |
| VIPD-Q | 1 | ≥2 (‘weekly’) on a 0 (‘never’) – 3 (‘daily’) scale | 1 [ | 848 | 28 | 250 | 8 | 1 | 0 |
| Question on dry eye | 1 | N/A | 1 [ | 43 | 44.2 | N/A | N/A | N/A | N/A |
| VFQ-25 | 2 | N/A | 3 [ | 145 | 27.3 [ | 466 | 22.4 [ | 2 [ | 1 [ |
| Online symptom survey (dry eyes) | 1 | ‘yes’ | 1 [ | 432 | 25.7 | N/A | N/A | N/A | N/A |
| Questions on visual complaints | N/A | N/A | 1 [ | 82 | 6.1 | N/A | N/A | N/A | N/A |
| OSDI | 12 | N/A | 1 [ | 100 | N/A | 100 | N/A | 1 | 0 |
| Blurred vision | 6 | 1695 | 19.7 – 46 | 630 | 7.4 – 19.0 | 4 | 0 | ||
| VIPD-Q | 1 | ≥2 (‘weekly’) on a 0 (‘never’) – 3 (‘daily’) scale | 1 [ | 848 | 46 | 250 | 12 | 1 | 0 |
| Symptom questionnaire | 1 | ‘yes’ | 1 [ | 181 | 36.2 | 263 | 19.0 | 1 | 0 |
| ADS (autonomic dysfunction score) | 1 | N/A | 1 [ | 21 | 28.6 | 27 | 7.4 | 1 | 0 |
| Interview on visual symptoms | 1 | ‘yes’ | 1 [ | 125 | 20 | N/A | N/A | N/A | N/A |
| Online symptom survey | 1 | ‘yes’ | 1 [ | 432 | 19.7 | N/A | N/A | N/A | N/A |
| Questionnaire derived from VFQ-25 | N/A | N/A | 1 [ | 88 | N/A | 90 | N/A | 1 | 0 |
| Changes in contrast sensitivity | 3 | 1157 | 8.8 – 27 | 319 | 10 – 13 | 2 | 0 | ||
| Questionnaire on changes in vision | 1 | ‘sometimes’ or ‘often’ | 1 [ | 184 | 27 | 69 | 13 | 1 | 0 |
| VIPD-Q | 1 | ≥2 (‘weekly’) on a 0 (‘never’) – 3 (‘daily’) scale | 1 [ | 848 | 26 | 250 | 10 | 1 | 0 |
| Interview on visual symptoms | 1 | ‘yes’ | 1 [ | 125 | 8.8 | N/A | N/A | N/A | N/A |
| Changes in size and shape perception | 3 | 982 | 3.7 – 19 | 281 | 5 – 13 | 2 | 0 | ||
| Questionnaire on changes in vision | 1 | ‘sometimes’ or ‘often’ | 1 [ | 53 | 19g | 31 | 13 | 1 | 0 |
| VIPD-Q | 1 | ≥2 (‘weekly’) on a 0 (‘never’) – 3 (‘daily’) scale | 1 [ | 848 | 17 | 250 | 5 | 1 | 0 |
| Questions on visual complaints | N/A | N/A | 1 [ | 82 | 3.7 | N/A | N/A | N/A | N/A |
| Changes in depth perception | 3 | 926 | 17 – 26 | 304 | 2 – 6 | 3 | 1 | ||
| Questionnaire on changes in vision | 1 | ‘sometimes’ or ‘often’ | 1 [ | 53 | 26 | 31 | 6 | 1 | 0 |
| VIPD-Q | 1 | ≥2 (‘weekly’) on a 0 (‘never’) – 3 (‘daily’) scale | 1 [ | 848 | 17 | 250 | 2 | 1 | 0 |
| VAQ | 3 | N/A | 1 [ | 25 | N/A | 23 | N/A | 1e | 1f |
| Reduced peripheral vision | 3 | 82 | N/A | 399 | N/A | 3 | 1 | ||
| VFQ-25 | 1 | N/A | 2 [ | 57 | N/A | 376 | N/A | 2 | 0 |
| VAQ | 5 | N/A | 1 [ | 25 | N/A | 23 | N/A | 1e | 1f |
| Difficulty estimating spatial relations | 3 | 390 | 6.4 – 50 | 69 | 28 | 1 | 0 | ||
| Questionnaire on changes in vision | 1 | ‘sometimes’ or ‘often’ | 1 [ | 184 | 50 | 69 | 28 | 1 | 0 |
| Self-report questionnaire (31-item) | 1 | ‘sometimes’ or ‘often’ | 1 [ | 81 | 45.0 | N/A | N/A | N/A | N/A |
| Interview on visual symptoms | 1 | ‘yes’ | 1 [ | 125 | 6.4 | N/A | N/A | N/A | N/A |
| Visual field impairment | 2 | 930 | 6.1 – 9 | 250 | 2 | 1 | 0 | ||
| VIPD-Q | 1 | ≥2 (‘weekly’) on a 0 (‘never’) – 3 (‘daily’) scale | 1 [ | 848 | 9 | 250 | 2 | 1 | 0 |
| Questions on visual complaints | N/A | N/A | 1 [ | 82 | 6.1 | N/A | N/A | N/A | N/A |
| Watery eyes | 2 | 930 | 26.8 – 31 | 250 | 15 | 1 | 0 | ||
| VIPD-Q | 1 | ≥2 (‘weekly’) on a 0 (‘never’) – 3 (‘daily’) scale | 1 [ | 848 | 31 | 250 | 15 | 1 | 0 |
| Questions on visual complaints | N/A | N/A | 1 [ | 82 | 26.8 | N/A | N/A | N/A | N/A |
| Changes in motion perception | 2 | 237 | 23.7 | 100 | 3 | 2 | 0 | ||
| Questionnaire on changes in vision | 1 | ‘sometimes’ or ‘often’ | 2 [ | 237 | 23.7 | 100 | 3 | 2 | 0 |
| Reduced night vision | 2 | 869 | 16 – 47.6 | 277 | 3 – 18.5 | 2 | 0 | ||
| ADS (autonomic dysfunction score) | 1 | N/A | 1 [ | 21 | 47.6 | 27 | 18.5 | 1 | 0 |
| VIPD-Q | 1 | ≥2 (‘weekly’) on a 0 (‘never’) – 3 (‘daily’) scale | 1 [ | 848 | 16 | 250 | 3 | 1 | 0 |
| Reduced light/dark adaptation | 2 | 873 | 27 | 273 | 11 | 2 | 1 | ||
| VIPD-Q | 1 | ≥2 (‘weekly’) on a 0 (‘never’) – 3 (‘daily’) scale | 1 [ | 848 | 27 | 250 | 11 | 1 | 0 |
| VAQ | 4 | N/A | 1 [ | 25 | N/A | 23 | N/A | 1e | 1f |
| Floaters | 2 | 178 | N/A | 122 | N/A | 0 | 2 | ||
| Questionnaire derived from VFQ-25 | N/A | N/A | 2 [ | 178 | N/A | 122 | N/A | 0 | 2 |
| Misjudge objects | 2 | 178 | N/A | 122 | N/A | 2 | 0 | ||
| Questionnaire derived from VFQ-25 | N/A | N/A | 2 [ | 178 | N/A | 122 | N/A | 2 | 0 |
| Asthenopia (ocular fatigue) | 1 | 39 | 43.6 | 39 | 5.1 | 1 | 0 | ||
| Questions on asthenopia | N/A | Presence of visual discomfort, diplopia, blurred vision or headache when reading | 1 [ | 39 | 43.6 | 39 | 5.1 | 1 | 0 |
| Hard to follow quick movements with the eyes | 1 | 848 | 25 | 250 | 4 | 1 | 0 | ||
| VIPD-Q | 1 | ≥2 (‘weekly’) on a 0 (‘never’) – 3 (‘daily’) scale | 1 [ | 848 | 25 | 250 | 4 | 1 | 0 |
| Need to turn head to side to see peripheral objects | 1 | 53 | 43 | 31 | 14 | 1 | 0 | ||
| Questionnaire on changes in vision | 1 | ‘sometimes’ or ‘often’ | 1 [ | 53 | 43 | 31 | 14 | 1 | 0 |
| Mucus/slime or particles in eyes or eyelids | 1 | 848 | 20 | 250 | 6 | 1 | 0 | ||
| VIPD-Q | 1 | ≥2 (‘weekly’) on a 0 (‘never’) – 3 (‘daily’) scale | 1 [ | 848 | 20 | 250 | 6 | 1 | 0 |
| Reduced acuity/spatial vision | 1 | 25 | N/A | 23 | N/A | 1 | 1 | ||
| VAQ | 4 | N/A | 1 [ | 25 | N/A | 23 | N/A | 1e | 1f |
| Reduced visual processing speed | 1 | 25 | N/A | 23 | N/A | 1 | 1 | ||
| VAQ | 6 | N/A | 1 [ | 25 | N/A | 23 | N/A | 1e | 1f |
| Reduced visual search | 1 | 25 | N/A | 23 | N/A | 0 | 1 | ||
| VAQ | 5 | N/A | 1 [ | 25 | N/A | 23 | N/A | 0 | 1 |
|
| |||||||||
| Reading difficulties | 6 | 1176 | 18.3 – 42.0 | 403 | 5.6 – 9.7 | 4 | 0 | ||
| Self-report questionnaire (31-item) | N/A | N/A | 1 [ | 81 | 42.0 | N/A | N/A | N/A | N/A |
| Questionnaire on visual complaints (20-item) | N/A | N/A | 1 [ | 30 | 26.7 | 31 | 9.7 | 1 | 0 |
| Questions on asthenopia | N/A | N/A | 1 [ | 39 | 23.1 | N/A | N/A | N/A | N/A |
| VIPD-Q | 1 | ≥2 (‘weekly’) on a 0 (‘never’) – 3 (‘daily’) scale | 1 [ | 848 | 18.3h | 250 | 5.6h | 1 | 0 |
| Questionnaire derived from VFQ-25 | N/A | N/A | 2 [ | 178 | N/A | 122 | N/A | 2 | 0 |
| Near activities | 5 | 1875 | 34.5 – 44.3 | 114558 | 9.7 – 25.5 | 5 | 0 | ||
| Survey of Health, Ageing, and Retirement in Europe | 1 | ≥4 on a 1 (‘excellent’) – 5 (‘poor’) scale | 1 [ | 1438 | 44.3 | 113802 | 25.5 | 1 | 0 |
| CISS | 14 | ≥21 | 2 [ | 380 | 34.5 | 380 | 9.7 | 2 | 0 |
| VFQ-25 | 3 | N/A | 2 [ | 57 | N/A | 376 | N/A | 2 | 0 |
| Difficulty/freezing in narrow spaces | 4 | 415 | 67.3 | 222 | 1.6 | 4 | 0 | ||
| Questionnaire on changes in vision | 1 | ‘sometimes’ or ‘often’ | 2 [ | 237 | 67.3i | 100 | 1.6i | 2 | 0 |
| Questionnaire derived from VFQ-25 | N/A | N/A | 2 [ | 178 | N/A | 122 | N/A | 2 | 0 |
| Distance activities | 3 | 1495 | 38.6 | 114178 | 15.0 | 3 | 0 | ||
| Survey of Health, Ageing, and Retirement in Europe | 1 | ≥4 on a 1 (‘excellent’) – 5 (‘poor’) scale | 1 [ | 1438 | 38.6 | 113802 | 15.0 | 1 | 0 |
| VFQ-25 | 3 | N/A | 2 [ | 57 | N/A | 376 | N/A | 2 | 0 |
| Driving | 3 | 94 | 21.6 | 355 | 2.7 | 3 | 0 | ||
| VFQ-25 | 2 | N/A | 2 [ | 57 | N/A | 318 | N/A | 2 | 0 |
| Self-report driving questionnaire derived from Charlton et al. (2006) [ | N/A | ‘very difficult’ in low visibility conditions | 1 [ | 37 | 21.6 | 37 | 2.7 | 1 | 0 |
| Difficulty reaching for objects | 1 | 184 | 46 | 69 | 3 | 1 | 0 | ||
| Questionnaire on changes in vision | 1 | ‘sometimes’ or ‘often’ | 1 [ | 184 | 46 | 69 | 3 | 1 | 0 |
| Problems with visual ADLs | 1 | 25 | N/A | 23 | N/A | 1 | 1 | ||
| VAQ | 33 | N/A | 1 [ | 25 | N/A | 23 | N/A | 1e | 1f |
|
| |||||||||
| Vision-specific social functioning | 2 | 57 | N/A | 376 | N/A | 2 | 0 | ||
| VFQ-25 | 2 | N/A | 2 [ | 57 | N/A | 376 | N/A | 2 | 0 |
| Vision-specific role difficulties | 2 | 57 | N/A | 376 | N/A | 1 | 1 | ||
| VFQ-25 | 2 | N/A | 2 [ | 57 | N/A | 376 | N/A | 1 [ | 1 [ |
| Vision-specific dependency | 2 | 57 | N/A | 376 | N/A | 2 | 0 | ||
| VFQ-25 | 3 | N/A | 2 [ | 57 | N/A | 376 | N/A | 2 | 0 |
| Vision-specific mental health | 2 | 57 | N/A | 376 | N/A | 2 | 0 | ||
| VFQ-25 | 4 | N/A | 2 [ | 57 | N/A | 376 | N/A | 2 | 0 |
Per complaint, each self-report measure used to describe this complaint is presented individually, along with the number of visual items it includes and the criterion that must be fulfilled for people to belong to the group with visual complaints. Weighted averages (prevalence of visual complaints) are presented for each complaint. References to the studies are placed in brackets []. ADLs, activities of daily living; CIRS-G, Cumulative Illness Rating Scale-Geriatric; CISS, Convergence Insufficiency Symptom Survey; COMPASS, Composite Autonomic Symptom Score; ICF, International Classification of Functioning; N, number/population size; N/A, not available; NMSQ, Non-Motor Symptoms Questionnaire, NMSS = Non-Motor Symptom Scale, OSDI = Ocular Surface Disease Index, PD = Parkinson’s disease, PRO-PD = Patient Reported outcomes in Parkinson’s Disease; QoL, quality of life; SCOPA-AUT, SCales for Outcomes in PArkinson’s disease– autonomic dysfunction; VAQ, Visual Activities Questionnaire; VFQ-25, Visual Function Questionnaire (25-item); VIPD-Q, Visual Impairment in Parkinson’s Disease Questionnaire. a Difference in score or prevalence between the groups, b Weighted prevalence of complaints on the ICF functions ‘seeing functions’ (72.9%) and ‘difficulty with watching’ (78.2%), c Items that may to some extent have arisen from motor symptoms (e.g., bumping into objects and freezing in narrow spaces) were included in the analysis. Prevalence was 57% after removing these items, dKhedr et al. (2012) [90] & Khedr et al. (2013) [55], and Giorelli et al. (2014) [65] & Giorelli et al. (2014) [66] used the same group of people with PD and reported the same results. For this reason, results of only one of these studies was reported, e Results only account for the non-tremor group (N = 12), f Results only account for the tremor group (N = 13), g Weighted prevalence of complaints on size (17%) and shape perception (21%), h Weighted prevalence of reading related complaints: ‘letters disappear while reading’ (20% in patients and 5% in controls) and ‘read better with one eye closed’ (17% in patients and 6% in controls), iWeighted prevalence of the complaints freezing (60% in patients and 3% in controls) and difficulty at doorways (56% in patients and 3% in controls) [119].
Relationship of demographic and disease-related variables with visual complaints
| Visual complaint | Significant positive relationship | Significant negative relationship | No significant relationship | |
|
| ||||
| 1. Age | Studies | 1 | 0 | 3 |
| Double vision | 0 | 0 | 2 [ | |
| Increased sensitivity to light | 0 | 0 | 1 [ | |
| Reduced visual health status | 1 [ | 0 | 0 | |
| 2. Gender (+men > women) | Studies | 1 | 0 | 12 |
| Visual complaints in general | 0 | 0 | 1 [ | |
| Double vision | 0 | 0 | 10 [ | |
| Increased sensitivity to light | 0 | 0 | 1 [ | |
| Altered color vision | 1 [ | 0 | 0 | |
| Difficulty estimating spatial relations | 1 [ | 0 | 0 | |
| 3. Education | Studies | 0 | 0 | 1 |
| Double vision | 0 | 0 | 1 [ | |
| 4. Disease duration | Studies | 6 | 0 | 3 |
| Visual complaints in general | 2 [ | 0 | 1 [ | |
| Double vision | 3 [ | 0 | 1 [ | |
| Increased sensitivity to light | 1 [ | 0 | 1 [ | |
| Altered color vision | 0 | 0 | 1 [ | |
| Difficulty estimating spatial relations | 0 | 0 | 1 [ | |
| Asthenopia | 0 | 0 | 1 [ | |
| 5. Disease severity | Studies | 12 | 0 | 6 |
| Visual complaints in general | 0 | 0 | 1 [ | |
| Double vision | 5 [ | 2 [ | ||
| Increased sensitivity to light | 4 [ | 4 [ | ||
| Altered color vision | 0 | 1 [ | ||
| Difficulty estimating spatial relations | 0 | 1 [ | ||
| Asthenopia | 1 [ | 0 | 0 | |
| Reduced visual health status | 2 [ | 0 | 0 | |
| Bumping into objects | 0 | 0 | 1 [ | |
| 6. Motor fluctuations | Studies | 2 | 0 | 0 |
| Double vision | 2 [ | 0 | 0 | |
| 7. Dominant symptom (+PIGD > tremor dominant) | Studies | 2 | 0 | 7 |
| Double vision | 1 [ | 0 | 6 [ | |
| Increased sensitivity to light | 0 | 0 | 1 [ | |
| Altered color vision | 0 | 0 | 1 [ | |
| Changes in depth perception | 1 [ | 0 | 0 | |
| Reduced peripheral vision | 0 | 0 | 1 [ | |
| Reduced light/dark adaptation | 1 [ | 0 | 0 | |
| Reduced acuity/spatial vision | 0 | 0 | 1 [ | |
| Reduced visual processing speed | 0 | 0 | 1 [ | |
| Reduced visual search | 0 | 0 | 1 [ | |
| Problems with visual ADLs | 1 [ | 0 | 0 | |
| 8. Dyskinesia | Studies | 1 | 0 | 0 |
| Double vision | 1 [ | 0 | 0 | |
| 9. Left vs. right onset PD | Studies | 0 | 0 | 1 |
| Double vision | 0 | 0 | 1 [ | |
| 10. Young vs. late onset PD (+late onset > young onset) | Studies | 2 | 0 | 2 |
| Double vision | 2 [ | 0 | 2 [ | |
| 11. Idiopathic PD vs. gene-related parkinsonism (LRRK2 [ | Studies | 1 | 0 | 3 |
| Double vision | 1 [ | 0 | 2 [ | |
| Increased sensitivity to light | 0 | 0 | 1 [ | |
| 12. Camptocormia | Studies | 1 | 0 | 1 |
| Double vision | 1 [ | 0 | 1 [ | |
|
| ||||
| 13. LEDD | Studies | 1 | 1 | 5 |
| Double vision | 0 | 1 [ | 1 [ | |
| Reduced visual health status | 1 [ | 0 | 0 | |
| Increased sensitivity to light | 0 | 0 | 1 [ | |
| 14. Off vs. on state (+off state > on state) | Studies | 3 | 0 | 0 |
| Visual complaints in general | 1 [ | 0 | 0 | |
| Double vision | 1 [ | 0 | 0 | |
| Problems focusing | 1 [ | 0 | 0 | |
| 15. Specific medical treatment (Pergolide and Benzhexol [ | Studies | 1 | 0 | 2 |
| Double vision | 0 | 0 | 2 [ | |
| Adverse visual effects | 1 [ | 0 | 0 | |
| 16. DBS (subthalamic nucleus) | Studies | 0 | 2 | 0 |
| Double vision | 0 | 2 [ | 0 | |
|
| ||||
| 17. QoL and ADL | Studies | 0 | 5 | 1 |
| Visual complaints in general | 0 | 1 [ | 0 | |
| Double vision | 0 | 1 [ | 0 | |
| Increased sensitivity to light | 0 | 3 [ | 1 [ | |
| 18. Consultation of medical doctor for eye problem | Studies | 1 | 0 | 1 |
| Bumping into objects | 1 [ | 0 | 0 | |
| Dry eyes | 0 | 0 | 1 [ | |
Supplementary Table 2 provides an overview of investigated relationships per complaint. >, first group reported more visual complaints than second group; ADL, activities of daily living; DBS, Deep Brain Stimulation; LEDD, Levodopa Equivalent Daily Dose; N, number of studies; PIGD, postural instability and gait disorder; QoL, quality of life. aSide of onset influenced the relationship of gender with difficulty estimating spatial relations; the difference between males and females was bigger (and significant) for the left onset group than right onset group (not significant), bDisease severity measured by Hoehn & Yahr classification and Clinical Impression of Severity Index for Parkinson’s Disease (CISI-PD) [151], cDisease severity measured by Cumulative Illness Rating Scale – Geriatrics (CIRS-G) [151], dOnly significant when adjusted for disease duration and dopaminergic treatment duration and dose [70], eResult accounts for a group of patients with late onset PD [79], fResult accounts for a group of patients with young onset PD [79], gNot significant when adjusted for age, gender, disease duration, disease severity, dopamine agonist, and levodopa [33], hMore colorful dreams were reported after using Pergolide, and relaxation of the eye muscles and blurry vision after using Benzhexol [119].